Skip to main content

Table 3 The correlation of variables with GVHD incidence in allogeneic HSCT recipients

From: Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia

Variables

Severe aGVHD

Extensive cGVHD

Incidence (%)

r

P value

Incidence (%)

r

P value

Gender

 

0.293

0.134

 

0.319

0.060

 Male

5/14 (35.7%)

  

3/14 (21.4%)

  

 Female

1/10 (10%)

  

0/10

  

Age, years

 

0.05

0.807

 

0.033

0.872

 ≥ 20

2/9 (22.2%)

  

1/9 (11.1%)

  

 < 20

4/15 (26.7%)

  

2/15 (13.3%)

  

Donor-recipient relationship

 

0.083

0.599

 

0.055

0.465

 Mother–child

3/12 (25%)

  

2/12 (16.7%)

  

 Father–child

2/5 (25%)

  

0/5

  

 Siblings

1/7 (14.3%)

  

1/7 (14.3%)

  

Patient/donor pair

 

0.225

0.566

 

0.541

0.022

 3 HLA loci

3/16 (18.8%)

  

0/16

  

 2 HLA loci

2/6 (33.3%)

  

2/6 (33.3%)

  

 1 HLA loci

1/2 (50%)

  

1/2 (50%)

  

Severe aGVHD

    

0.364

0.099

 Yes

   

2/6 (33.3%)

  

 No

   

1/18 (5.6%)

  
  1. HSCT hematopoietic stem cell transplantation, aGVHD acute graft-versus-host disease, cGVHD chronic graft-versus-host disease, HLA human leukocyte antigen